Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

54.23 +0.02 (+0.03%)
Streaming Delayed Price Updated: 1:02 PM EST, Dec 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
84 85 Next >
News headline image
2 Unstoppable Dividend Growth Stocks You Can Buy Now With $100 ↗
These dividend payers could more than double their payouts in the decade ahead. 
Via The Motley Fool
News headline image
FDA Battles Backlog of Drug Factory Inspections Since COVID-19 ↗
FDA faces inspection backlog with serious public health implications, as critical drug manufacturing plants remain unchecked. 
Via Benzinga
News headline image
Bristol Myers Squibb Employees to Relay Nearly 3,000 Miles Cross-Country Aspiring to Raise Over $1 Million for the V Foundation for Cancer Research
From Bristol Myers Squibb
Via Business Wire
News headline image
Market Whales and Their Recent Bets on BMY Options ↗
 
Via Benzinga
News headline image
Key Takeaways From Bristol-Myers Squibb Analyst Ratings ↗
 
Via Benzinga
News headline image
Bristol-Myers Squibb's Options Frenzy: What You Need to Know ↗
 
Via Benzinga
News headline image
Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs ↗
Despite Medicare's first-ever negotiated drug prices under the Inflation Reduction Act, U.S. costs remain significantly higher than those in other wealthy nations, with some prices still more than... 
Via Benzinga
Topics Economy
News headline image
2 Reasons Bristol Myers Squibb Stock Could Be a Bargain, Down 34% From Its All-Time High ↗
Rebounding growth could make shares of this leading drugmaker a big winner. 
Via The Motley Fool
News headline image
2 No-Brainer Large-Cap Stocks to Buy With $500 Right Now ↗
No stock is perfect, but quality businesses can stand the test of time in your portfolio. 
Via The Motley Fool
News headline image
Long-Term Follow-Up Data from Phase 3 Study of CAMZYOS® (mavacamten) Underscores Established Efficacy and Safety Profile in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
From Bristol Myers Squibb
Via Business Wire
News headline image
Check Out What Whales Are Doing With BMY ↗
 
Via Benzinga
News headline image
Stock Market Rally Mixed; Dow Jones Hits High While Nvidia Tumbles On Earnings: Weekly Review ↗
The Dow Jones hit a new high while Nvidia led a Nasdaq retreat. 
Via Investor's Business Daily
Topics Stocks
News headline image
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet ↗
The Benzinga Stock Whisper Index looks at five stocks seeing above average interest from investors during the week. 
Via Benzinga
News headline image
As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors ↗
Neurocrine Biosciences reports Phase 2 trial results for NBI-1117568 showing significant improvement in schizophrenia symptoms, with an 18.2-point reduction in PANSS scores at a 20 mg dose. 
Via Benzinga
News headline image
Kohl's Posts Upbeat Q2 Earnings, Joins Box, Waldencast, AeroVironment And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Neurocrine Bio Dives As Schizophrenia Trial Results Lags Peers ↗
As new schizophrenia drugs move toward approval, Neurocrine Biosciences reports a subpar outcome for its phase 2 trial. 
Via Investor's Business Daily
News headline image
3 High-Yield Dividend Stocks With Payout Ratios Below 75% ↗
Unlock steady income and growth potential with these high-yield, low-risk dividend powerhouses. 
Via The Motley Fool
News headline image
2 Beaten-Down S&P 500 Dividend Stocks to Buy on the Dip and Hold Forever ↗
These underappreciated dividend payers offer yields above 4% at recent prices. 
Via The Motley Fool
Topics Stocks
News headline image
Regulators Expected To Approve Innovative Schizophrenia Treatment From Bristol Myers, Karuna ↗
Drug companies are investing in schizophrenia treatments as patients are desperate for a drug that has few side effects, Bloomberg reports. 
Via Benzinga
News headline image
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Squibb to Present Data Across Cardiovascular Portfolio at the European Society of Cardiology Congress 2024
From Bristol Myers Squibb
Via Business Wire
News headline image
Cancer Medicines From Merck, Bristol Myers And BeiGene In Question, As FDA Committee To Discuss Limiting PD-1 Drugs For Stomach Cancer ↗
The FDA's Oncologic Drugs Advisory Committee will meet on September 26 to reevaluate the approvals of checkpoint inhibitors for advanced gastric, gastroesophageal junction adenocarcinoma, and... 
Via Benzinga
News headline image
Bristol Myers Squibb Receives U.S. Food and Drug Administration sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular Carcinoma
From Bristol Myers Squibb
Via Business Wire
News headline image
Merck's Stock Dip Offers a Buying Opportunity: Here’s Why
Global big pharmaceutical company Merck & Co. Inc. (NYSE: MRK) shares sank 9% following its Q2 2024 earnings release. Merck beat top and bottom line estimates, 
Via MarketBeat
Topics Intellectual Property
News headline image
3 High-Yield Dividend Stocks You Can Buy With $200 Now and Hold at Least a Decade ↗
With yields above 4%, these stocks could do a lot to boost your passive income stream 
Via The Motley Fool
News headline image
European Medicines Agency Validates Bristol Myers Squibb’s Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
From Bristol Myers Squibb
Via Business Wire
News headline image
Where Will Bristol Myers Squibb Be in 5 Years? ↗
The drugmaker will go through key changes by the end of the decade. 
Via The Motley Fool
News headline image
3 High-Yield Dividend ETFs to Buy to Generate Passive Income ↗
ETFs offer a good way to own a diversified portfolio of income-producing equities. 
Via The Motley Fool
Topics ETFs
News headline image
Biden Administration Targets $6B Savings Through Medicare Drug Price Negotiations ↗
Medicare drug price negotiations, enabled by the Inflation Reduction Act, are set to save the U.S. government $6 billion. 
Via Benzinga
Topics Economy
News headline image
Bristol Myers' German Partner Evotec Plans Layoffs, Cites 'Challenging Revenues, Profitability' ↗
Evotec reports a rise in Q2 sales to $201.12M but posts an EPS loss of $0.54. CEO Christian Wojczewski cites market challenges and outlines cost-cutting measures, including a 7% workforce reduction. 
Via Benzinga
Topics Workforce
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
84 85 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.